Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -22.20% is 450% below its 5-year average of 6.35%, near the low end of its 5-year range (-22.20%–21.25%).
798.11% below its 12-month average of 3.18%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -24.44%.
RETURN ON ASSETS (ROA)
-22.20%
RETURN ON ASSETS (ROA) AVG TTM
3.18%
RETURN ON ASSETS (ROA) AVG 3Y
2.72%
RETURN ON ASSETS (ROA) AVG 5Y
6.35%
RETURN ON ASSETS (ROA) AVG 10Y
-1.80%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-798.11%
CURRENT VS 3Y AVG
-915.43%
CURRENT VS 5Y AVG
-449.79%
CURRENT VS 10Y AVG
-1132.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+31.14%
vs the sector median at left
Organogenesis Holdings Inc.
Market Cap
$172.42M
Return on Assets (ROA)
-22.20%
TTM Avg
3.18%
3Y Avg
2.72%
5Y Avg
6.35%
Market Cap
$174.46M
Return on Assets (ROA)
-79.26%
TTM Avg
-73.67%
3Y Avg
-58.36%
5Y Avg
-102.57%
Market Cap
$171.13M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
Market Cap
$173.76M
Return on Assets (ROA)
-32.29%
TTM Avg
-23.28%
3Y Avg
-25.06%
5Y Avg
-27.38%
Market Cap
$169.53M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$168.92M
Return on Assets (ROA)
-28.07%
TTM Avg
-34.40%
3Y Avg
-29.52%
5Y Avg
-36.05%
Market Cap
$168.10M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$165.27M
Return on Assets (ROA)
-34.75%
TTM Avg
-23.73%
3Y Avg
-25.63%
5Y Avg
-26.84%
Market Cap
$179.26M
Return on Assets (ROA)
47.31%
TTM Avg
7.73%
3Y Avg
-1.35%
5Y Avg
-4.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | $172.42M | -22.20% | 3.18% | 2.72% | 6.35% |
| Yarrow Bioscience Inc (YARW)vs › | $174.46M | -79.26% | -73.67% | -58.36% | -102.57% |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | -41.88% | -12.18% | -27.40% | -32.78% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -32.29% | -23.28% | -25.06% | -27.38% |
| Journey Medical Corporation (DERM)vs › | $169.53M | -6.21% | -15.18% | -15.88% | -16.43% |
| MediWound Ltd. (MDWD)vs › | $168.92M | -28.07% | -34.40% | -29.52% | -36.05% |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | -534.43% | -94.69% | -82.47% | -71.30% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -34.75% | -23.73% | -25.63% | -26.84% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | 47.31% | 7.73% | -1.35% | -4.55% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 2.80% | -4.42% | -6.73% | -5.05% |
ROA
-22.2%
ROE
-31.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 6.19% |
| 2024-12-31 | 0.17% |
| 2023-12-31 | 1.07% |
| 2022-12-31 | 3.46% |
| 2021-12-31 | 21.25% |
| 2020-12-31 | 5.94% |
| 2019-12-31 | -17.54% |
| 2018-12-31 | -39.61% |
| 2017-12-31 | -0.67% |
| 2016-12-31 | -0.07% |
| 2015-12-31 | 0.00% |
